Shanghai Bioprofile Technology Company, Ltd. (“Bioprofile”) recently has announced the completion of hundred millions of CNY in Series A funding.
Bioprofile is an international first-class provider of proteomics, metabolomics, genomics, and transcriptomics technology services. Committed to promoting the development of related scientific research fields through products and services, helping research experts overcome major challenges brought by omics research and precision medical research, and benefiting humanity.
According to Bioprofile, it could lay out multiple technology platforms and application fields and provides a one-stop solution for clinical mass spectrometry through proteomics and metabolomics, including comprehensive solutions for multi omics technology research (proteomics, metabolomics, etc.), instruments, reagents, preprocessing platforms, software, and technical services. Meanwhile, it deeply integrating with clinical needs, we provide broader development space for proteomics and metabolomics technology services.
According to Mordor Intelligence, the global market size of Clinical Mass Spectrometry was worth USD 785.6 million in 2020, it is predicted to reach 1,242.3 million billion by 2026, with a compound annual growth rate of 7.9%. This growth is driven by the technological advancements in mass spectrometer devices, growing concerns over food safety around the world and increasing research and development expenditure by both government and private entities.
In addition to Bioprofile, many companies are competing in the mass spectrometry market, such as Agilent Technologies, PerkinElmer, Danaher Corporation (Sciex), Waters Corporation in the United States, Shimadzu Corporation in Japan, Hiden Analytical in the United Kingdom, and Analytik Jena in Germany.
This round of financing for Bioprofile was exclusively invested by Zhong Hui Jin (上海中汇金资本), with follow-on investment from Shanghai Venture Relay Technology (创业接力基金). This round of funds will mainly be used for the research and development of clinical mass spectrometry detection and biomarker development, as well as to strengthen the expansion of clinical mass spectrometry and multi omics research and development teams, and enhance the company's core competitiveness.